Pediatric Nephrology Clinical Trials
||A Phase 3, Randomized, OpenLabel, Multicenter Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy, and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects with Chronic Kidney Disease (CKD)
||This is a Phase 3, randomized, open-label, multicenter, study of the safety (compared to iron sucrose), efficacy, and PK/PD of ferumoxytol (7.0 mg Fe/kg x 2 [max 510 mg/dose]) in pediatric subjects with iron deficiency anemia (IDA) and CKD. There will be a total of approximately 125 subjects randomized to treatment in a 2:1 ratio to either ferumoxytol or iron sucrose
|WA43380||A Phase III, International, Multicenter, Randomised Open Label Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Patients With Childhood Onset Idiopathic Nephrotic Syndrome||This open-label, randomized multicenter study is to assess the efficacy, safety, and pharmacokinetics (PK)/pharmacodynamics (PD) of obinutuzumab compared with mycophenolate mofetil (MMF) in children and young adults (aged >= 2-25 years) with frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS)
||A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS) (COMMUTE-p)
||This study aims to evaluate the efficacy and safety of crovalimab in pediatric participants with aHUS.
||ULTRA-Peds: A Multicenter Data Registry for Outcomes for Pediatric Volume Overload
||The objectives of the ULTRA-Peds registry is to further understand the performance and utilization of Aquadex in local standard of care, and to characterize the safety and feasibility of using Aquadex in local standard of care.